Official UK visa sponsor profile for Cerevance Limited in Cambridge, including current register status, route details, and public company data.
Cerevance Limited is a UK-based limited company established in 2016, currently registered under SIC code 10304008. The company specializes in the research and development of novel therapeutics targeting Central Nervous System (CNS) disorders. Cerevance operates within the pharmaceutical industry, focusing on the creation of innovative treatments for conditions affecting the brain and spinal cord. The company’s core competency lies in utilizing the NETSseq platform, a proprietary technology, to identify and validate potential drug targets and therapies. Cerevance’s services encompass preclinical research, including assay development, data analysis, and pathway analysis, supporting the identification of novel therapeutic candidates. Cerevance’s primary focus is on developing symptomatic and disease-modifying therapies for a range of CNS conditions, with a particular emphasis on neurological and psychiatric diseases. The company is actively engaged in international collaborations and partnerships to accelerate drug discovery and development. Cerevance’s size estimate is currently considered to be mid-sized, reflecting its dedicated research and development team. Cerevance’s international presence is currently facilitated through strategic partnerships and collaborations, indicating a commitment to global therapeutic innovation.
Official UK visa sponsor profile for Cerevance Limited in Cambridge, including current register status, route details, and public company data.
Cerevance Limited is a UK-based limited company established in 2016, currently registered under SIC code 10304008. The company specializes in the research and development of novel therapeutics targeting Central Nervous System (CNS) disorders. Cerevance operates within the pharmaceutical industry, focusing on the creation of innovative treatments for conditions affecting the brain and spinal cord. The company’s core competency lies in utilizing the NETSseq platform, a proprietary technology, to identify and validate potential drug targets and therapies. Cerevance’s services encompass preclinical research, including assay development, data analysis, and pathway analysis, supporting the identification of novel therapeutic candidates. Cerevance’s primary focus is on developing symptomatic and disease-modifying therapies for a range of CNS conditions, with a particular emphasis on neurological and psychiatric diseases. The company is actively engaged in international collaborations and partnerships to accelerate drug discovery and development. Cerevance’s size estimate is currently considered to be mid-sized, reflecting its dedicated research and development team. Cerevance’s international presence is currently facilitated through strategic partnerships and collaborations, indicating a commitment to global therapeutic innovation.
Yes, Cerevance Limited is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
Cerevance Limited is classified under: Research and experimental development on biotechnology.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.
Yes, Cerevance Limited is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
Cerevance Limited is classified under: Research and experimental development on biotechnology.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.